New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
The Latest on: Cancer Immunotherapy
via Google News
The Latest on: Cancer Immunotherapy
- Immunotherapy Drugs Market is Anticipated to Cross US$ 289.52 Billion by 2024 on April 17, 2019 at 7:00 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- New York, April 17, 2019: Immunotherapy refers to treatments that stimulate, beautify or suppress the body’s personal immune system. Cancer segment is ... […]
- Iteos advancing adenosine antagonist as cancer immunotherapy in phase I/Ib on April 16, 2019 at 9:18 pm
LONDON - Iteos Therapeutics SA has joined the growing band of companies seeking to reverse tumor immune evasion by blocking the anti-inflammatory effects of adenosine signaling, with dosing of the ... […]
- UCSD patient gets first cancer treatment made from stem cells on April 16, 2019 at 7:58 am
A new form of cancer immunotherapy has been given to a University of California, San Diego Health patient in the first test of immune cells grown from stem cells. The patient, Derek Ruff ... […]
- Dr. Socinski on New Applications of Immunotherapy in NSCLC on April 15, 2019 at 1:38 pm
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer (NSCLC). In ... […]
- Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer on April 15, 2019 at 8:54 am
Recently, various clinical trials have honed in on the use of immunotherapy to treat triple-negative breast cancer. The results of several such studies were presented at the European Society of ... […]
- Cancer Immunotherapy Market to attain a value of US$124.88 billion by 2024 - TMR on April 15, 2019 at 5:15 am
Albany, NY, Apr 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Albany, NY, April 15, 2019 (GLOBE NEWSWIRE) -- According to TMR, the global cancer immunotherapy market is estimated to expand at a CAGR of 14.6 ... […]
- Cancer cells use tactics to avoid being recognised by immunotherapy agents on April 14, 2019 at 11:53 pm
Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy ... […]
- New Target for Cancer Immunotherapy: Exosomes on April 9, 2019 at 6:08 am
It was once a central tenet of biology that RNA molecules did their work inside the cell. But it’s now clear that RNA molecules are also active outside the cell, with potentially major implications ... […]
- Kidney cancer immunotherapy combo approved for NHS use in England on April 5, 2019 at 11:27 am
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England. The decision to approve the treatment follows an ... […]
- Cancer Immunotherapy May Run Afoul of Exosomal Checkpoint Proteins on April 5, 2019 at 7:35 am
Checkpoint inhibition, a revolutionary cancer immunotherapy, works only in a minority of patients, and scientists want to know why it is resisted in the majority. At the UC San Francisco (UCSF), ... […]
via Bing News